feb jan dec nov oct sep fda drugs march zenvia involuntary emotional expression disorder avanir pharm received approvable letter last october zenvia combination drug dextromethorphan quinidine dm used treat otherwise known labile affect pseudobulbar affect brain condition one uncontrollable bursts laughing crying without truly happy sad typically occurs stroke pseudobulbar palsy als fda required data company recently provided meeting dm nmda antagonist quinidine used p cypd enzyme inhibitor makes drug stick around longer fda asked avanir resubmit new nda lower safer dose pubmed cephalon gets yet another warning letter provigil fda dinged cephalon feb letter inappropriate marketing claims suggesting provigil effective certain conditions data submitted approved fda marijuana based drug gathering data sativex oral spray containing two active compounds cannabis sativa plant developed several conditions including ms related spasticity aids related anorexia neuropathic pain given fact directly derived pot plants paranoia marijuana i sure drug long uphill battle get approved pubmed prozac labeling change infants labeling information prozac fluoxetine added info risk primary pulmonary hypotension pph drug exposed newborns precautions pregnancy nonteratogenic effects infants exposed ssris late pregnancy may increased risk persistent pulmonary hypertension newborn pphn pphn occurs per live births general population associated substantial neonatal morbidity mortality retrospective case control study women whose infants born pphn women whose infants born healthy risk developing pphn approximately six fold higher infants exposed ssris th week gestation compared infants exposed antidepressants pregnancy currently corroborative evidence regarding risk pphn following exposure ssris pregnancy first study investigated potential risk study include enough cases exposure individual ssris determine ssris posed similar levels pphn risk i know ssris get language link goes original nejm article new fda info sheets invega paliperidone keppra levetiracetam trileptal oxcarbazepine permax recalled fda announced dopamine agonist permax pergolide voluntarily recalled due concerns damage heart valves permax used treat parkinson disease restless legs syndrome phase iii trials started flurizan alzheimer looks like promising drug myriad keep track geodon label updated labeling info geodon ziprasidone updated patient summary section include black box warning diabetes also include recent indications manic mixed episodes bipolar disorder symmetrel label updated apparently reports agranulocytosis dangerous drop white blood cell wbc count symmetrel amantadine used antiviral parkinsons pain probably things labeling info reflects fda adds warnings sleeping pills fda asked makers sedative hypnotics like ambien sonata lunesta add warnings labels anaphylaxis severe allergic reaction angioedema severe facial swelling occur early first time product taken complex sleep related behaviors may include sleep driving making phone calls preparing eating food asleep warning affects following drugs manufacturers ambien ambien cr sanofi aventis butisol sodium medpointe pharm hlc carbrital parke davis dalmane valeant pharm doral questcor pharms halcion pharmacia upjohn lunesta sepracor placidyl abbott prosom abbott restoril tyco healthcare rozerem takeda seconal lilly sonata king pharmaceuticals